|
substance to the pharmacy from which the subsequent controlled |
substance is sought. |
(c) A person may be in violation of Section 3.23 of the |
Illinois Food, Drug and Cosmetic Act or Section 406 of this Act |
when medication shopping or pharmacy shopping, or both. |
(c-5) Each Effective January 1, 2018, each prescriber |
possessing an Illinois controlled substances license shall |
register with the Prescription Monitoring Program. A |
prescriber is not subject to criminal liability or |
professional discipline for failure to register with the |
Prescription Monitoring Program due to technological or |
electrical failures or operational issues that prevent |
registration. Notwithstanding any provision of this Act to the |
contrary, beginning on and after the effective date of this |
amendatory Act of the 101st General Assembly, a licensed |
veterinarian shall be exempt from registration and prohibited |
from accessing patient information in the Prescription |
Monitoring Program. Licensed veterinarians that are existing |
registrants shall be removed from the Prescription Monitoring |
Program. Each prescriber or the prescriber's his or her |
designee shall also document an attempt to access patient |
information in the Prescription Monitoring Program to assess |
patient access to controlled substances when providing an |
initial prescription for any stimulant substances listed in |
Schedule II and all prescriptions an initial prescription for |
Schedule II opioids and Schedule IV benzodiazepine, narcotics |
|
such as opioids, except for prescriptions for oncology |
treatment or palliative care, or a 7-day or less supply |
provided by a hospital emergency department when treating a an |
acute, traumatic medical condition. This attempt to access |
shall be documented in the patient's medical record. The |
hospital shall facilitate the designation of a prescriber's |
designee for the purpose of accessing the Prescription |
Monitoring Program for services provided at the hospital. |
(d) When a person has been identified as having 5 or more |
prescribers or 5 or more pharmacies, or both, that do not |
utilize a common electronic file as specified in Section 20 of |
the Pharmacy Practice Act for controlled substances within the |
course of a 6-month period, the Prescription Monitoring |
Program may issue an unsolicited report to the prescribers, |
dispensers, and their designees informing them of the |
potential medication shopping. If an unsolicited report is |
issued to a prescriber or prescribers, then the report must |
also be sent to the applicable dispensing pharmacy. |
(e) Nothing in this Section shall be construed to create a |
requirement that any prescriber, dispenser, or pharmacist |
request any patient medication disclosure, report any patient |
activity, or prescribe or refuse to prescribe or dispense any |
medications. |
(f) This Section shall not be construed to apply to |
inpatients or residents at hospitals or other institutions or |
to institutional pharmacies. |
|
(g) Any patient feedback, including grades, ratings, or |
written or verbal statements, in opposition to a clinical |
decision that the prescription of a controlled substance is |
not medically necessary shall not be the basis of any adverse |
action, evaluation, or any other type of negative |
credentialing, contracting, licensure, or employment action |
taken against a prescriber or dispenser. |
(Source: P.A. 101-414, eff. 8-16-19; 102-527, eff. 8-20-21.) |